![]() Vansteenkiste points out that long-term results are even more promising. ![]() And mortality risk decreases by 38% in metastasized NSCLC.” Promising In treatment-naive patients immune therapy almost doubles the 5-year survival compared to chemotherapy (31.9% vs. Well, the results for this group of patients exceed expectations. Around 1 in 3 NSCLC tumours have a high PD-L1 expression and are therefore suitable for immune therapy. “Included patients presented lung tumours with a high PD-L1 count, a protein on the cell membrane that serves as a reliable indicator to predict the probability of success of immune therapy. Professor Johan Vansteenkiste, respiratory oncologist at UZ Leuven explains what the trial was about and what the results are. Recently, the results of the Keynote-024 study were presented, a long-term large scale trial concerning the use of immune therapy in advanced and/or metastasized NSCLC. Presently, around 1 in every 3 new lung cancer diagnoses in Belgium is treated with immune therapy, either as monotherapy or in combination with other treatments. Response rates are almost 5 times those of chemotherapy, and mortality risk decreases by 38%, And immune therapy comes with considerably fewer adverse side effects compared to chemotherapy (31.2% vs 53.3%). In the most common type of lung cancer, non-small cell lung cancer or NSCLC, five-year survival is almost doubled thanks to immune therapy drugs. ![]() However, the advent of immune therapy in 2016 brought about huge changes and improvement in overall survival. Lung cancer has always been one of the most prevalent cancers in Belgium, and also the one with the highest death toll in absolute numbers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |